High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity

Molecular Pharmacology

Volumn 70, Issue 1, 2006, Pages 23-29

  Thomas, Jan Peter ^a   Lautermann, Juergen ^a   Liedert, Bernd ^a   Seiler, Frank ^b   Thomale, Juergen ^a,c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Squarix GmbH   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYGUANINE; CARBOPLATIN; CISPLATIN; GUANINE; PLATINUM; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COCHLEA; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA CROSS LINKING; DNA DAMAGE; DRUG EXPOSURE; EPITHELIUM CELL; GUINEA PIG; IMMUNOFLUORESCENCE TEST; INNER EAR; KIDNEY CELL; NONHUMAN; OTOTOXICITY; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SHORT COURSE THERAPY; STRIA VASCULARIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TRANSFORMED; CELLS, CULTURED; CISPLATIN; DNA ADDUCTS; EAR, INNER; EPITHELIAL CELLS; GUANOSINE; GUINEA PIGS; HYDROGEN PEROXIDE; INJECTIONS, INTRAPERITONEAL; KIDNEY TUBULES; KINETICS; MICROSCOPY, FLUORESCENCE; PLATINUM; RATS; STRIA VASCULARIS; TISSUE DISTRIBUTION;

EID: 33745278586     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.022244     Document Type: Article

References (38)

1. Barzilai A and Yamamoto K (2004) DNA damage responses to oxidative stress. DNA Repair 3:1109-1115.
2. Bertolini P, Lassale M, Mercier G,Raquim MA, Izzi G, Corradini N, and Hartmann O (2004) Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26:649-655.
3. Boulikas T and Vougiouka M (2003) Cisplatin and platinum drugs at the molecular level. Oncol Rep 10:1663-1682.
4. Buschfort-Papewalis C, Moritz T, Liedert B, and Thomale J (2002) Down-regulation of DNA repair in human CD34(+) progenitor cells corresponds to increased drug sensitivity and apoptotic response. Blood 100:845-853.
5. Dehne N, Lautermann J, Petrat F, Rauen U, and de Groot H (2001) Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol 174:27-34.
6. Dobyan DC, Levi J, Jacobs C, Kosek J, and Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 213:551-556.
7. Evans P and Halliwell B (1999) Free radicals and hearing. Cause, consequence and criteria. Ann NY Acad Sci 884:19-40.
8. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, and Pommier Y (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62:4899-4902.
9. Gedik CM and Collins A (2005) Establishing the background level of base oxidation in human lymphocyte DNA: results of an interlaboratory validation study. FASEB J 19:82-84.
10. Hatzopoulos S, Di Stefano M, Albertin A, and Martini A (1999) Evaluation of cisplatin ototoxicity in a rat animal model. Ann NY Acad Sci 884:211-225.
11. Husain K, Whitworth C, Somani SM, and Rybak LP (2001) Carboplatin-induced oxidative stress in rat cochlea. Hear Res 159:14-22.
12. Kelland LR (1993) New platinum antitumor complexes. Crit Rev Oncol Hematol 15:191-219.
13. Laurell G and Engstrom B (1989) The ototoxic effect on guinea pigs in relation to dosage. Hear Res 38:27-33.
14. Lee JE, Nagakawa T, Kita T, Kim TS, Iguchi F, Endo T, Shiga A, Lee SH, and Ito J (2004) Mechanisms of apoptosis induced by cisplatin in marginal cells in mouse stria vascularis. ORL (Basel) 66:111-118.
15. Liedert B, Materna V, Schadendorf D, Thomale J, and Lage H (2003) Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Investig Dermatol 121:172-176.
16. Liedert B, Pluim D, Schellens J, and Thomale J (2006) Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res, in press
17. Lynch ED, Gu R, Pierce C, and Kil J (2005) Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 201:81-89.
18. Materna V, Liedert B, Thomale J, and Lage H (2005) Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int J Cancer 115:393-402.
19. McDonald ES and Windebank AJ (2002) Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis 9:220-233.
20. McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf 13:228-244.
21. Meech RP, Campbell KC, Hughes LP, and Rybak LP (1998) A semiquantitative analysis of the effects of cisplatin on the rat stria vascularis. Hear Res 124:44-59.
22. Minami SB, Sha SH, and Schacht J (2004) Antioxidant protection in a new animal model of cisplatin-induced ototoxicity. Hear Res 198:137-143.
23. Nehls P, Seiler F, Rehn B, Greferath R, and Bruch J (1997) Formation and persistence of 8-oxoguanine in rat lung cells as an important determinant for tumor formation following particle exposure. Environ Health Perspect 105 Suppl 5:1291-1296.
24. Safaei R and Howell SB (2005) Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 53:13-23.
25. Saito T and Aran JM (1994) Comparative ototoxicity of cisplatin during acute and chronic treatment. ORL (Basel) 56:315-320.
26. Schweitzer VG (1993) Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 103:1-52.
27. Schweitzer VG, Rarey KE, Dolan DF, Abrams GE, and Sheridan C (1986) Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9). Otolaryngol Head Neck Surg 94:458-470.
28. Seiler F, Kirstein U, Eberle G, Hochleitner K, and Rajewsky MR (1993) Quantification of specific DNA-alkylation products in individual cells by monoclonal antibodies and digital imaging of intensified nuclear fluorescence. Carcinogenesis 14:1907-1913.
29. Seiler F, Rehn B, Rehn S, Hermann M, and Bruch J (2001) Quartz exposure of the rat lung leads to a linear dose response in inflammation but not in oxidative DNA damage and mutagenicity. Am J Respir Cell Mol Biol 24:492-498.
30. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279.
31. Tange RA and Vuzevski VD (1984) Changes in the stria vascularis of the guinea pig due to cis-platinum. Arch Otorhinolaryngol 239:41-47.
32. Thomale J, Engelbergs J, Seiler F, and Rajewsky MF (1996) Monoclonal antibodybased quantification and repair analysis of specific alkylation products in DNA, in Technologies for Detection of DNA Damage and Mutations (Pfeifer GP ed) pp 87-101, Plenum, New York.
33. Uehara T, Watanabe H, Itoh F, Inoue S, Koshida H, Nakamura M, Yamate J, and Maruyama T (2005) Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol 79:451-460.
34. van Ruijven MW, de Groot JC, Hendriksen F, and Smoorenburg GF (2005) Immunohistochemical detection of platinated DNA in the cochlea of cisplatin-treated guinea pigs. Hear Res 203:112-121.
35. van Ruijven MW, de Groot JC, and Smoorenburg GF (2004) Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration. A quantitative histological study. Hear Res 197:44-54.
36. Watanabe K, Jinnouchi K, Hess A, Michel O, Baba S, and Yagi T (2002) Carboplatin induces less apoptosis in the cochlea of guinea pigs than cisplatin. Chemotherapy 48:82-87.
37. Wu X, Fan W, Xu S, and Zhou Y (2003) Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells. Clin Cancer Res 9:5874-5879.
38. Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T, and Inui KI (2005) Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 70:1823-1831.